EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy

Judith van Deutekom, Chantal Beekman, Suzanne Bijl, Sieto Bosgra, Rani van den Eijnde, Dennis Franken, Bas Groenendaal, Bouchra Harquouli, Anneke Janson, Paul Koevoets, Melissa Mulder, Daan Muilwijk und 11 weitere

Nucleic Acid Therapeutics · 01.06.2023 · 33 (3) · 193-208

DOI: 10.1089/nat.2022.0063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 02.06.2023. Verfasst von Judith van Deutekom und 22 weiteren Autor:innen. Beteiligte Einrichtung: VICO Therapeutics B.V., formerly BioMarin Nederland B.V., Leiden, The Netherlands. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last two decades, antisense oligonucleotides (AONs) that induce corrective exon skipping have matured as promising therapies aimed at tackling the dystrophin deficiency that underlies the severe and progressive muscle fiber degeneration in Duchenne muscular dystrophy (DMD) patients. Pioneering first generation exon 51 skipping AONs like drisapersen and eteplirsen have more recently been followed up by AONs for exons 53 and 45, with, to date, a total of four exon skipping AON drugs having reached (conditional) regulatory US Food and Drug Administration (FDA) approval for DMD. Nonetheless, considering the limited efficacy of these drugs, there is room for improvement. The aim of this study was to develop more efficient [2′- O -methyl-modified phosphorothioate (2′OMePS) RNA] AONs for DMD exon 51 skipping by implementing precision chemistry as well as identifying a more potent target binding site. More than a hundred AONs were screened in muscle cell cultures, followed by a selective comparison in the hDMD and hDMDdel52/ mdx mouse models. Incorporation of 5-methylcytosine and position-specific locked nucleic acids in AONs targeting the drisapersen/eteplirsen binding site resulted in 15-fold higher exon 51 skipping levels compared to drisapersen in hDMDdel52/ mdx mice. However, with similarly modified AONs targeting an alternative site in exon 51, 65-fold higher skipping levels were obtained, restoring dystrophin up to 30% of healthy control. Targeting both sites in exon 51 with a single AON further increased exon skipping (100-fold over drisapersen) and dystrophin (up to 40%) levels. These dystrophin levels allowed for normalization of creatine kinase (CK) and lactate dehydrogenase (LDH) levels, and improved motor function in hDMDdel52/ mdx mice. As no major safety observation was obtained, the improved therapeutic index of these next generation AONs is encouraging for further (pre)clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneMiceAnimalsDystrophinOligonucleotides, AntisenseMice, Inbred mdxGenetic TherapyExons

Stichwörter der Autor:innen

Duchenne muscular dystrophyantisense oligonucleotidedystrophinexon skipping

Substanzen

DystrophinOligonucleotides, Antisense

Autor:innen und Institutionen

  • VICO Therapeutics B.V., formerly BioMarin Nederland B.V., Leiden, The Netherlands.
  • Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
  • Charles River Discovery Services, Kuopio, Finland.
  • BioMarin Pharmaceutical, Inc., San Rafael, California, USA.

ORCID-Profile: Annemieke Aartsma-Rus

Zitieren

APA

van Deutekom, J., Beekman, C., Bijl, S., Bosgra, S., van den Eijnde, R., Franken, D., Groenendaal, B., Harquouli, B., Janson, A., Koevoets, P., Mulder, M., Muilwijk, D., Peterburgska, G., Querido, B., Testerink, J., Verheul, R., de Visser, P., Weij, R., Aartsma-Rus, A., …, & Datson, N. A. (2023). Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy. Nucleic Acid Therapeutics, 33(3), 193-208. https://doi.org/10.1089/nat.2022.0063

Vancouver

van Deutekom J, Beekman C, Bijl S, Bosgra S, van den Eijnde R, Franken D, et al. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy. Nucleic Acid Therapeutics. 2023;33(3):193-208. doi:10.1089/nat.2022.0063

BibTeX
@article{vanDeutekom2023,
  author = {van Deutekom, Judith and Beekman, Chantal and Bijl, Suzanne and Bosgra, Sieto and van den Eijnde, Rani and Franken, Dennis and Groenendaal, Bas and Harquouli, Bouchra and Janson, Anneke and Koevoets, Paul and Mulder, Melissa and Muilwijk, Daan and Peterburgska, Galyna and Querido, Bianca and Testerink, Janwillem and Verheul, Ruurd and de Visser, Peter and Weij, Rudie and Aartsma-Rus, Annemieke and Puoliväli, Jukka and Bragge, Timo and O'Neill, Charles and Datson, Nicole A},
  title = {Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy},
  journal = {Nucleic Acid Therapeutics},
  year = {2023},
  volume = {33},
  number = {3},
  pages = {193--208},
  doi = {10.1089/nat.2022.0063}
}
Kostenlos starten →